Miguel Martín
YOU?
Author Swipe
View article: Supplementary Figure S2 from <i>CCNE1</i> and <i>PLK1</i> Mediate Resistance to Palbociclib in HR+/HER2− Metastatic Breast Cancer
Supplementary Figure S2 from <i>CCNE1</i> and <i>PLK1</i> Mediate Resistance to Palbociclib in HR+/HER2− Metastatic Breast Cancer Open
Patients’ characteristics and Progression Free Survival comparison. Biomarker Cohort and PEARL Study Population
View article: Supplementary Figure S3 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
Supplementary Figure S3 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients Open
Supplementary Figure 3. Survival analysis in baseline population (C1D1) on TP53 mutations, within the population with any detectable mutation (n=146).
View article: Supplementary Table S12 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
Supplementary Table S12 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients Open
Supplementary Table 12. Baseline genomic landscape of mutations distribution for the CDR population (n=120), by number of mutations or presence/absence, across treatment arms.
View article: Supplementary Figure S2 from Triple-Negative PAM50 Non-Basal Breast Cancer Subtype Predicts Benefit from Extended Adjuvant Capecitabine
Supplementary Figure S2 from Triple-Negative PAM50 Non-Basal Breast Cancer Subtype Predicts Benefit from Extended Adjuvant Capecitabine Open
Supplementary Figure S2 shows a forest plot comparing basal vs. non-basal subtype as defined by PAM50 or by IHC, and their associations with disease free survival on capecitabine vs. observation arm.
View article: Supplementary Figure S6 from <i>CCNE1</i> and <i>PLK1</i> Mediate Resistance to Palbociclib in HR+/HER2− Metastatic Breast Cancer
Supplementary Figure S6 from <i>CCNE1</i> and <i>PLK1</i> Mediate Resistance to Palbociclib in HR+/HER2− Metastatic Breast Cancer Open
PALOMA-3 study as validation dataset
View article: Supplementary Tables S1-S10 from Triple-Negative PAM50 Non-Basal Breast Cancer Subtype Predicts Benefit from Extended Adjuvant Capecitabine
Supplementary Tables S1-S10 from Triple-Negative PAM50 Non-Basal Breast Cancer Subtype Predicts Benefit from Extended Adjuvant Capecitabine Open
Supplementary Table S1 shows the gene list for the NanoString custom nCounter codeset included in the study. Supplementary Table S2 shows patient characteristics in the GEICAM/CIBOMA translational study cohort versus the original trial. Su…
View article: Supplementary Figure S5 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
Supplementary Figure S5 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients Open
Supplementary Figure 5. CDR and clinical benefit rate within the longitudinal predictive ctDNA analysis.
View article: Supplementary Data S1-S2 from Triple-Negative PAM50 Non-Basal Breast Cancer Subtype Predicts Benefit from Extended Adjuvant Capecitabine
Supplementary Data S1-S2 from Triple-Negative PAM50 Non-Basal Breast Cancer Subtype Predicts Benefit from Extended Adjuvant Capecitabine Open
Supplementary Data S1 shows exploratory analysis for the predictive capacity of the continuous expression of additional genes and metagenes included in the codeset. Supplementary Data S2 shows exploratory analysis for the prognostic capaci…
View article: Supplementary Figure S4 from Triple-Negative PAM50 Non-Basal Breast Cancer Subtype Predicts Benefit from Extended Adjuvant Capecitabine
Supplementary Figure S4 from Triple-Negative PAM50 Non-Basal Breast Cancer Subtype Predicts Benefit from Extended Adjuvant Capecitabine Open
Supplementary Figure S4 shows a forest plot of the exploratory categorical analysis of selected (meta)gene expression and their association with disease free survival on the capecitabine arm vs. observation.
View article: Supplementary Figure S4 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
Supplementary Figure S4 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients Open
Supplementary Figure 4. OS analysis in baseline population (C1D1) on ESR1 and PIK3CA mutations, within the population with any detectable mutation (N=146).
View article: Supplementary Figure S4 from <i>CCNE1</i> and <i>PLK1</i> Mediate Resistance to Palbociclib in HR+/HER2− Metastatic Breast Cancer
Supplementary Figure S4 from <i>CCNE1</i> and <i>PLK1</i> Mediate Resistance to Palbociclib in HR+/HER2− Metastatic Breast Cancer Open
Progression Free Survival analysis on CCNE1 expression levels under palbociclib plus ET treatment
View article: Supplementary Table S9 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
Supplementary Table S9 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients Open
Supplementary Table 9. Summary of PFS results for ESR1 and PIK3CA mutations. Cox regression univariate and multivariate analysis.
View article: Supplementary Figure S5 from <i>CCNE1</i> and <i>PLK1</i> Mediate Resistance to Palbociclib in HR+/HER2− Metastatic Breast Cancer
Supplementary Figure S5 from <i>CCNE1</i> and <i>PLK1</i> Mediate Resistance to Palbociclib in HR+/HER2− Metastatic Breast Cancer Open
Analysis of gene expression associated with treatment benefit
View article: Supplementary Table S7 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
Supplementary Table S7 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients Open
Supplementary Table 7. Baseline genomic landscape of mutations distribution in population, by number of mutations or presence/absence, across treatment arms.
View article: Supplementary Figure S11 from <i>CCNE1</i> and <i>PLK1</i> Mediate Resistance to Palbociclib in HR+/HER2− Metastatic Breast Cancer
Supplementary Figure S11 from <i>CCNE1</i> and <i>PLK1</i> Mediate Resistance to Palbociclib in HR+/HER2− Metastatic Breast Cancer Open
Volasertib overcomes resistance to fulvestrant and palbociclib in PLK1-overexpressing ER+ breast cancer cells
View article: Supplementary Figure S3 from Triple-Negative PAM50 Non-Basal Breast Cancer Subtype Predicts Benefit from Extended Adjuvant Capecitabine
Supplementary Figure S3 from Triple-Negative PAM50 Non-Basal Breast Cancer Subtype Predicts Benefit from Extended Adjuvant Capecitabine Open
Supplementary Figure S3 shows a forest plot of the exploratory categorical analysis of selected (meta)gene expression and their association with distant recurrence free survival on the capecitabine arm vs. observation.
View article: Genomic tests to guide management of breast cancer in Europe: regulation, reimbursement, adoption, and challenges
Genomic tests to guide management of breast cancer in Europe: regulation, reimbursement, adoption, and challenges Open
The integration of genomic tests such as the Oncotype DX Breast Recurrence Score® test, into routine clinical practice represents a significant advance in personalized breast cancer care. By supporting more tailored therapeutic decisions, …
View article: The Prognostic and Predictive Impact of Circulating Tumour DNA Levels in Patients with Advanced Breast Cancer Enrolled on the plasmaMATCH Trial
The Prognostic and Predictive Impact of Circulating Tumour DNA Levels in Patients with Advanced Breast Cancer Enrolled on the plasmaMATCH Trial Open
Purpose: Circulating tumour DNA(ctDNA) dynamic levels may identify patients who will respond to therapy. We assessed ctDNA baseline levels and on-treatment dynamics in advanced breast cancer patients on the plasmaMATCH trial with mutation …
View article: Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive/HER2-negative early breast cancer: 5-year follow-up of NATALEE efficacy outcomes and updated overall survival
Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive/HER2-negative early breast cancer: 5-year follow-up of NATALEE efficacy outcomes and updated overall survival Open
This prespecified 5-year follow-up of efficacy outcomes from NATALEE demonstrated that ribociclib + NSAI continued to reduce the risk of recurrence beyond the 3-year treatment window, supporting its use as adjuvant therapy in patients with…
View article: Supplementary Appendix S1 from FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial
Supplementary Appendix S1 from FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial Open
Nonauthor Collaborators
View article: Supplementary Table S3 from FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial
Supplementary Table S3 from FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial Open
Receiver operating characteristics (ROC) curves data of FOXC1 Score (VFOXC1) versus IHC phenotype and PAM50 intrinsic subtype in basal-like/non-basal categories definitions
View article: Supplementary Figure S1 from FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial
Supplementary Figure S1 from FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial Open
Survival analyses showing the secondary endpoint of disease-free survival (DFS) for patients randomly assigned to capecitabine or observation in the GEICAM_CIBOMA translational study cohort
View article: Data from FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial
Data from FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial Open
Purpose:In a prespecified GEICAM_CIBOMA trial (NCT00130533) correlative analysis, PAM50 non–basal-like breast cancer (non-BLBC) status distinguished patients with triple-negative breast cancer (TNBC) who are most likely to benefit from adj…
View article: Supplementary Figure S3 from FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial
Supplementary Figure S3 from FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial Open
Forest plot for the GEICAM_CIBOMA translational study cohort primary endpoint of recurrence-free survival (RFS) on the capecitabine arm versus observation arm for basal-like/non-basal categories variables
View article: Supplementary Table S8 from FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial
Supplementary Table S8 from FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial Open
Multivariate Cox regression analysis of 5-year and 8-year recurrence-free survival (RFS) for basal-like/non-basal categories variables in the GEICAM_CIBOMA translational study cohort
View article: Supplementary Table S2 from FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial
Supplementary Table S2 from FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial Open
Patient’s distribution by VFOXC1 and Ki67
View article: Supplementary Table S4 from FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial
Supplementary Table S4 from FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial Open
Inter-assay agreement assessment by Kappa index between basal-like/non-basal categories variables
View article: Supplementary Figure S2 from FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial
Supplementary Figure S2 from FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial Open
Survival analyses showing the secondary endpoint of overall survival (OS) for patients randomly assigned to capecitabine or observation in the GEICAM_CIBOMA translational study cohort
View article: Supplementary Table S9 from FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial
Supplementary Table S9 from FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial Open
Disease-free survival (DFS) events for basal-like/non-basal subpopulations by VFOXC1 in the GEICAM_CIBOMA translational analysis
View article: Supplementary Table S6 from FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial
Supplementary Table S6 from FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial Open
Multivariate Cox regression analysis of disease-free survival (DFS) for basal-like/non-basal categories variables in the GEICAM_CIBOMA translational study cohort